Long-term follow-up after prior Caribou treatment
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal representative) must sign consent before any study tasks
- You must have completed a Caribou-sponsored study or received Caribou medicine through a special access program or investigator-initiated study
- If you could become pregnant, you must use effective birth control for 12 months after the infusion
- If you have a partner who could become pregnant, your partner must also use effective birth control for 12 months after the infusion
- If you are a man with a partner who could become pregnant, you and your partner must both use effective birth control for 12 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who have already received a CRISPR CAR T cell therapy to monitor their long-term health and any side effects. It helps doctors understand how these treatments work over time.
This study checks in with people who already received CAR-T therapy to learn how they’re doing over time. It may help doctors understand the long-term benefits and side effects of CAR-T for future patients.
This trial tests combining an experimental pill (CC-99282) with the immunotherapy drug rituximab for people with B-cell non-Hodgkin's lymphoma whose cancer did not fully respond to CAR-T cell therapy. The goal is to improve results after CAR-T.
This is a follow-up study for people age 18 or older who previously took part in a CAR T-cell gene therapy trial. It helps researchers check your health over time after that treatment and supports long-term safety and outcomes tracking.
This study monitors participants who received a certain type of CAR T-cell therapy for cancer. It helps researchers understand long-term effects and safety.
This study follows children and young adults who received CAR T-cell therapy for B-cell ALL at least two years ago. It checks long-term side effects, how well the therapy worked over time, and quality of life, so doctors can better understand the lasting impacts of CAR T-cells.
Hear when a new Relapsed Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.